Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EPS (Weighted Average and Diluted) (2022 - 2024)

CervoMed's EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.55 for Q3 2024.

  • For Q3 2024, EPS (Weighted Average and Diluted) rose 21.43% year-over-year to -$0.55; the TTM value through Sep 2014 reached -$0.3, up 19.56%, while the annual FY2022 figure was $2.0 million, 4.73% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2024 was -$0.55 at CervoMed, up from -$0.7 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.0 million in Q4 2022 and bottomed at -$0.7 in Q3 2023.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.55 (2024), against an average of $679632.7.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 21.43% in 2024 against a maximum downside of 21.43% in 2024.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $2.0 million in 2022, then tumbled by 100.0% to -$0.7 in 2023, then rose by 21.43% to -$0.55 in 2024.
  • Per Business Quant, the three most recent readings for CRVO's EPS (Weighted Average and Diluted) are -$0.55 (Q3 2024), -$0.7 (Q3 2023), and $2.0 million (Q4 2022).